- Ainos ( NASDAQ: AIMD ) signed an agreement under which Swiss Pharmaceutical (Taiwan) will test, manufacture and package the company's Veldona product candidates for use in planned clinical trials.
- Ainos said it plans to submit an investigational new drug application to the U.S. FDA by the end of this year, for getting clearance to start a phase 2 study.
- The company said that it had started a phase 2 trial of Veldona in patients with mild COVID-19 in Taiwan, following results from preclinical studies of Veldona formulation against COVID-19 in June 2022.
- AIMD +16.67% to $2.94 premarket Aug. 17
For further details see:
Ainos stock rises 17% on contracting Swiss Pharma to make Veldona products for clinical trials